Biogen CFO Paul Clancy to Take Executive Post at Alexion Pharma

Paul Clancy, CFO of Biogen (NASDAQ: [[ticker:BIIB]]) for the last 10 years, is moving to Alexion Pharmaceuticals (NASDAQ: [[ticker:ALXN]]) to become the top financial executive of the New Haven, CT, drug developer. Before joining Cambridge, MA-based Biogen, Clancy held various executive positions at PepsiCo (NYSE: [[ticker:PEP]]).

Alexion says Clancy will start at the company on July 10. He will succeed CFO Dave Anderson, who will continue in his role until July 31. To help with Clancy’s transition, Anderson will remain with the company through August as a senior advisor to Alexion’s CEO.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times. View all posts by Frank Vinluan